Back to trials
completed
Phase 4

NCT01830517

Diurnal Variation in Hypertensive Stroke Patients

Sponsored by Hanmi Pharmaceutical Company Limited

Summary

This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with an acute ischemic stroke by measuring their 24-hour ambulatory BP (ABP).

Eligibility Criteria

Inclusion Criteria: 1. aged 35 to 85 years 2. hypertensive patients who had an ischemic stroke Exclusion Criteria: 1. patients aged below 35 years or above 86 years; 2. patients who had a hemorrhagic stroke; 3. patients whose systolic BP (SBP) was over 220 mmHg or whose diastolic BP (DBP) was above 120 mmHg during an acute phase, or whose SBP was over 180 mmHg or whose DBP was over 110 mmHg one week after their hospital visit; 4. patients with secondary hypertension related to renovascular, endocrinologic, or pregnant conditions 5. patients who went to bed in the middle of the day or very late at night; (6) patients who were using intravenous antico-agulants or thrombolytics; (7) patients with a severe stroke (NIH stroke scale \> 20); (8) patients who could not give their consent to investigators; (9) patients with severely impaired liver function (AST or ALT ≥ 100); (10) patients with severely impaired renal function (serum creatinine ≥ 2.0 mg/dL); (11) patients with cancer; (12) patients who were pregnant or lactating; (13) patients with other grave diseases such as hypertensive encephalopathy, aortic dissection, acute myocardial infarction, or severe congestive heart failure; and (14) patients who were allergic to the test or control drugs

Locations (1)

Boramae Medical Center

Boramae-ro 5-gil 20, Dongjak-gu, Seoul, South Korea

Why you can trust this information
Registry sourcesclinicaltrials_gov
Source last updated4/12/2013
Clintriva indexed9/27/2026, 9:23:16 PM
Registry records1
Relationships needing review0

Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.

Interested in this trial?

Express your interest and we'll connect you with the trial team.

Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.

Quick Facts
Start DateAug 1, 2007
CompletionJun 1, 2011
Enrollment0/84
CountrySouth Korea

Conditions

Hypertension
Stroke
View on registry
Clintriva
GDPR Controls Mapped HIPAA Safeguards Mapped NHS DSP Controls Mapped SOC 2 Controls Mapped

© 2026 Clintriva. All rights reserved.